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Abnormal motor behaviors in Parkinson’s disease (PD) result from striatal dysfunction due
to an imbalance between dopamine and glutamate transmissions that are integrated by
dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32). c-Abelson tyrosine
kinase (c-Abl) phosphorylates cyclin-dependent kinase 5 (Cdk5) at Tyr15 to increase the
activity of Cdk5, which reduces the efﬁcacy of dopaminergic signaling by phosphorylating
DARPP-32 at Thr75 in the striatum. Here, we report that in the mouse striatum, a novel
c-Abl inhibitor, nilotinib (AMN107), inhibits phosphorylation of both Cdk5 at Tyr15 and
DARPP-32 atThr75, which is negatively regulated by dopamine receptor activation through
a D2 receptor-mediated mechanism. Like a D2-agonist, nilotinib synergizes with a D1-
agonist for inducing striatal c-Fos expression. Moreover, systemic administration of nilotinib
normalizes striatal motor behaviors in a mouse model of PD induced by 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine. These ﬁndings suggest that nilotinib could possibly serve as a
new and alternative agent for treating PD motor symptoms.
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INTRODUCTION
Striatal dopamine deﬁciency caused by the degenerative loss
of nigral dopaminergic cells is the main pathological feature
of Parkinson’s disease (PD; Olanow and Tatton, 1999). The
pathophysiology of PD involves dysfunction of the striatum
due to an imbalance between dopamine and glutamate trans-
mission that have opposing physiological effects (Greengard,
2001). A key regulator in the integration of dopamine and
glutamate is DARPP-32, the dopamine- and cAMP-regulated
phosphoprotein of 32 kDa. DARPP-32 is a striatal-enriched
phosphoprotein, which can act as either a protein phosphatase
inhibitor or a protein kinase inhibitor, depending on whether
Thr34 or Thr75 is phosphorylated (Greengard, 2001). Corticostri-
atal glutamate inputs activate cyclin-dependent kinase 5 (Cdk5),
which inhibits postsynaptic dopamine signaling by phosphory-
lating DARPP-32 at Thr75 (Thr75-DARPP-32) in the striatum
(for reference, see Figure 1). DARPP-32 with Thr75 phos-
phorylation (DARPP-32-pThr75) functions as an inhibitor of
cAMP-dependent protein kinase A (PKA), a key regulator of
dopamine D1 receptor (D1R)-mediated signals. Given the evi-
dence that under resting conditions, striatal Thr75-DARPP-32 is
very highly phosphorylated, but striatal Thr34-DARPP-32 is only
slightly phosphorylated (Greengard, 2001; Sako et al., 2010), it
has been suggested that tonic activity of glutamate/Cdk5 signal-
ing might be responsible for maintaining Thr75-DARPP-32 in a
phosphorylated state, thereby inhibitingD1R/PKA signaling in the
striatum (Greengard, 2001). Interestingly, in rodent models of PD,
striatal dopamine deﬁciency has been shown to have no effect on
phosphorylation of Thr34-DARPP-32, but signiﬁcantly increase
that of Thr75-DARPP-32 (Brown et al., 2005; Santini et al.,
2007). These ﬁndings suggest that the glutamate/Cdk5/DARPP-
32-pThr75 pathwaymight be important in assessing themolecular
mechanisms underlying PD symptoms.
c-Abelson tyrosine kinase (c-Abl) is the prototypic non-
receptor tyrosine kinase that is implicated in various cellular
processes (Dhavan and Tsai, 2001; Hantschel and Superti-
Furga, 2004). Of particular interest is that c-Abl phosphory-
lates Cdk5 at Tyr15 to increase Cdk5 activity (Zukerberg et al.,
2000; Dhavan and Tsai, 2001; Zhang et al., 2007). We recently
found that in mice, Cdk5-pTyr15 is highly concentrated in
the striatum, particularly in its matrix compartment (Morigaki
et al., 2011; Yamamura et al., 2013), where dopamine receptor
activation negatively regulates phosphorylation of Tyr15-Cdk5
through a D2R-mediated mechanism (Yamamura et al., 2013).
Moreover, in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) mouse model of PD, the c-Abl inhibitor imatinib
(STI-571) reverses abnormally increased striatal phosphory-
lation of Tyr15-Cdk5 and Thr75-DARPP-32, as does L-3,4-
dihydroxyphenylalanine (L-DOPA; Yamamura et al., 2013). These
ﬁndings suggest a new hypothesis that c-Abl signaling might be
implicated in striatal function and raise the possibility that a c-
Abl inhibitor might inhibit Cdk5/DARPP-32-pThr75 signaling,
thereby serving as a tool in treating PD symptoms. In this
study, we report that nilotinib (formerly known as AMN107),
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FIGURE 1 | Striatal Cdk5/DARPP-32 signal regulation. Hypothesized
model shows striatal dopamine and glutamate neurotransmissions
involving postsynaptic dopamine/PKA/DARPP-32-pThr34 and
glutamate/Cdk5/DARPP-32-pThr75 signaling cascades. c-Abl inhibitors (e.g.,
nilotinib) target c-Abl that can activate Cdk5 by phosphorylating it at Tyr15.
a second-generation tyrosine kinase inhibitor that targets c-Abl
(Weisberg et al., 2006; Blay and von Mehren, 2011), can normal-
ize motor impairments caused by striatal dopamine deﬁciency in
MPTP-treated mice.
MATERIALS AND METHODS
ANIMALS
Male C57Bl/6 mice (Japan SLC Co., Shizuoka, Japan) aged 7–8
weekswere used in this study. Themicewere housed in a controlled
environment (25 ± 1◦C, 50 ± 10% humidity, and 12-h light/dark
cycle) with access to food and tap water ad libitum. All procedures
involving experimental mice were approved by the Ethical Review
Committee of the University of Tokushima.
NILOTINIB ADMINISTRATION
Mice received single intraperitoneal injections of nilotinib (5,
10, 25, or 50 mg/kg; Cayman Chemical, Ann Arbor, MI, USA)
dissolved in 0.5% aqueous carboxymethyl cellulose 3 days after
administration of MPTP or saline. Vehicle-treated (control) mice
received an equivalent volume of 0.5% aqueous carboxymethyl
cellulose.
ADMINISTRATION OF DOPAMINERGIC DRUGS
In combination with nilotinib (25 mg/kg), A-68930 hydrochloride
(2 mg/kg of free base; Sigma-Aldrich, St Louis, MO, USA), SCH-
23390 hydrochloride (0.5 mg/kg of free base; Sigma-Aldrich),
quinpirole hydrochloride (3 mg/kg of free base; Sigma-Aldrich),
or raclopride hydrochloride (1 mg/kg of free base; Sigma-Aldrich)
was dissolved in saline and intraperitoneally injected 30minbefore
sacriﬁce. The dose of each drug was determined as described
previously (Yamamura et al., 2013).
MPTP ADMINISTRATION
Micewere injected intraperitoneally four times in adaywithMPTP
hydrochloride (20 mg/kg of free base; Sigma-Aldrich) at 2-h inter-
vals (Aoki et al., 2009; Yamamura et al., 2013). Saline-treated mice
received an equivalent volume of 0.9% saline. Our previous study
showed that maximal neurodegenerative effects of MPTP on the
nigral dopaminergic cells were observed at the 3-day time-point
after administration of MPTP (Aoki et al., 2009; Yamamura et al.,
2013).
WESTERN BLOT ANALYSIS
Striatal tissue samples were homogenized in ice-cold lysis buffer
containing 50 mM Tris–HCl buffer, pH 7.5, with 0.5 M NaCl,
0.5% Triton X-100, 10 mM EDTA (ethylenediaminetetraacetic
acid), 4 mM EGTA (ethylene glycol tetraacetic acid), 1 mM
Na3VO4, 30 mM Na2P2O7, 50 mM NaF, 0.1 mM leupeptin,
75 μM pepstatin A, 50 μg/ml trypsin inhibitor, 1 mM phenyl-
methanesulfonyl ﬂuoride, 100 nM calyculin A, and 1 mM
dithiothreitol. After centrifugation at 15,000 rpm for 10 min
at 4◦C, the protein lysates were mixed with Laemmli’s buffer
containing 63 mM Tris–HCl, pH 6.8, 2% sodium dodecyl sul-
fate (SDS), 5% 2-mercaptoethanol, 2.5% glycerol, and 0.01%
bromophenol blue, and were then heated at 100◦C for 5 min.
Each sample, containing the same amount of protein, was
applied to a 10% SDS-polyacrylamide gel for electrophoresis
(PAGE) followed by blotting onto a PVDF (polyvinylidene ﬂu-
oride) membrane. The PVDF membranes were then incubated
with the desired primary antibodies. Antibodies against tyro-
sine hydroxylase (TH; 1:1000; Millipore, Billerica, MA, USA),
Cdk5-pTyr15 (1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), Cdk5 (1:1000; Santa Cruz Biotechnology), and DARPP-32
(1:1000; Cell Signaling, Danvers, MA, USA) DARPP-32-pThr34
(1:1000; Cell Signaling), and DARPP-32-pThr75 (1:1000; Cell
Signaling) were used. Anti-β-actin antibody (1:5000; Sigma-
Aldrich) was used to adjust for equal amounts of protein loading
into each well. The bound antibodies were detected by the
ECL (enhanced chemiluminescence) method with horseradish
peroxidase-conjugated secondary antibodies. Gel images were
captured using a lumino-imaging analyzer LAS-4000 (Fujiﬁlm,
Tokyo, Japan). Optical densities were evaluated using a com-
puterized image analysis system (Dolphin-DOC; Kurabo, Osaka,
Japan).
TISSUE PREPARATION AND c-Fos IMMUNOSTAINING
Mice were injected intraperitoneally with a lethal dose of pento-
barbital (Sigma-Aldrich) 120 min after drug administration. They
were then transcardially perfused with 0.01 M phosphate-buffered
saline (PBS) at pH 7.4, followed by cold 4% paraformaldehyde
in 0.1 M phosphate buffer (PB) at pH 7.4. The brains were
removed, post-ﬁxed overnight in the same ﬁxative at 4◦C, and
moved through a 10–30% sucrose gradient in 0.1 M PB at 4◦C
for cryoprotection. Sections were cut on a cryostat at 15-μm
thickness, and stored in PBS containing 0.05% NaN3 until use.
Free-ﬂoating brain sections were incubated in PBS containing
3% bovine serum albumin (BSA) and rabbit polyclonal antibody
to c-Fos (1:50,000; Oncogene Science, Cambridge, MA, USA) at
room temperature overnight. The bound primary antibodies were
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detected by the Histoﬁne Simple Stain Kit (Nichirei, Tokyo, Japan)
and theTSA (tyramide signal ampliﬁcation) systemwithCyanine3
(PerkinElmer; Shelton, CT, USA; Goto et al., 2013; Koizumi et al.,
2013).
DIGITAL IMAGING AND NUCLEAR DENSITOMETRY
Digitalmicroscopic imageswere captured using anOlympus BX51
microscope (Olympus, Tokyo, Japan), imported into Adobe Pho-
toshop CS4, and processed digitally for adjustments of contrast,
brightness, and color balance. Measurements of the density of
c-Fos-labeled nuclei were made on the striatal sections at the level
of 0.9–1.1 mm anterior to bregma, according to the atlas of Hof
et al. (2000). We counted the number of c-Fos-positive nuclei in
ﬁve striatal ﬁelds of each mouse (n = 5), and calculated the density
of c-Fos-positive nuclei/mm2 in each animal (Sako et al., 2010).
BEHAVIORAL TESTS
Prior to pharmacological testing, mice were handled for a week
by the same operator to reduce stress, and trained for behavioral
tests as described below until their motor performance became
reproducible. All behavioral training and tests were performed by
the same operator from 10:00 to 16:00 in the order to lower stress.
The experimental room environment was kept constant for all
tests. Apparatus was cleaned with 70% ethanol on each trial.
Beam walking test
This test evaluates motor coordination and balance in rodents.
The testing apparatus consists of a rough round horizontal beam
(wood, 8 mm diameter for test trial or 16 mm for training trial,
80 cm length) ﬁxed 60 cm above a countertop, and a dark goal box
(15 cm width, 10 cm length, 10 cm height). Mice were trained to
traverse the beam without stopping on the way for three consec-
utive days before MPTP administration. In test trials, mice were
made to traverse the beam in the same manner (cut-off time 60 s
maximum). The traveling time from the start to the 50 cm point
was recorded.
Bar test
This test is also known as the catalepsy test, and it estimates the
ability of an animal to escape from an externally imposed posture.
The testing apparatus consists of a horizontal metal bar (3 mm
diameter) ﬁxed 4 cm above a countertop. The forepaws of mice
were gently placed on the bar, and the time for which mice main-
tained this abnormal posture was measured (cut-off time 120 s
maximum). Training trial was performed once a day for three
consecutive days before MPTP administration. Testing trials were
performed in the same manner.
Horizontal wire test
This test estimates motor coordination and muscle relaxation. The
testing apparatus consists of a solid wire (1 mm diameter, 20 cm
length) horizontally stretched 20 cm above a countertop. Mice
were lifted by the tail and allowed to grasp the wire with their
forepaws, and then were released. A mouse passed this test if it
grasped the wire with at least one hindpaw within 3 s. Mice were
trained to pass the test for three consecutive days before MPTP
administration. The test trial was performed once in the same
manner. The rate of mice passing was recorded.
Rotarod test
This test evaluates motor coordination and motor learning. The
Rota-Rod Treadmill (Constant Speed Model, Ugo Basile, Varese,
Italy) was used. On the day before the training session started,
mice were habituated to the apparatus for 15 min. In training tri-
als, mice were trained to run on the rotarod (20 rpm) for 10 min
without falling, twice a day for three consecutive days beforeMPTP
administration. In test trials, mice were made to run the rod rotat-
ing at 28 rpm (cut-off time 600 s maximum). The latency time to
fall was recorded.
Foot printing test
This test provides information on locomotor gait. The testing
apparatus is made of a gray acrylic board (3 mm thick), and con-
sists of a runway (10 cm width, 60 cm length, 12 cm height)
with non-slippery white paper and a dark goal box (16 cm width,
10 cm length, 12 cm height). On the ﬁrst training day, mice were
habituated to the apparatus for 2 min, then their forepaws and
hindpaws were painted red and green with non-toxic food dyes
and trained to run to the goal box (training trial). A training trial
was performed once a day for two consecutive days before MPTP
administration. In test trials, mice were made to run the runway
in the same manner (cut-off time 60 s maximum). The foot-
print patterns were analyzed for three parameters (stride length,
stride width, and overlap), prints near the start and the goal being
excluded because of the effects of acceleration or deceleration.
Stride length was measured as the average distance between each
forepaw and hindpaw footprint. Stride width was measured as
the average distance between the right and left footprint of each
forepaw and hindpaw. Overlap was measured as the average dis-
tance between the center of forepaw andhindpaw footprints on the
same side. At least four values were measured in each trial for each
parameter.
STATISTICAL ANALYSIS
All experimental valueswere expressed asmeans± SEM. Statistical
signiﬁcancewas evaluated by unpaired two-tailed t-test, or by one-
way analysis of variance (ANOVA) followed by Newman–Keuls,
Scheffe, or Fisher’s PLSD (protected least signiﬁcant difference)
post hoc test for pairwise comparisons. The signiﬁcance level was
set at P < 0.05. All analyses were conducted in Stat View 5.0 (SAS
Institute, Cary, USA).
RESULTS
NILOTINIB INHIBITS STRIATAL PHOSPHORYLATION OF Tyr15-Cdk5 AND
Thr75-DARPP-32 IN NAÏVE MICE
To test whether nilotinib could affect striatal phosphorylation of
Cdk5 and DARPP-32, we ﬁrst performed western blot analysis on
the striatal extracts from mice that received intraperitoneal injec-
tions of vehicle or nilotinib at doses of 5, 10, 25, or 50 mg/kg
30 min before they were sacriﬁced. Striatal levels of Cdk5-
pTyr15 (Figure 2A; P < 0.05, ANOVA) and DARPP-32-pThr75
(Figure 2B; P < 0.05, ANOVA) were signiﬁcantly reduced in mice
injected with nilotinib at the doses of 25 and 50 mg/kg, compared
to mice treated with vehicle. In contrast, no effects of nilotinib
on striatal levels of total Cdk5 (Figure 2A; P > 0.05, ANOVA),
DARPP-32-pThr34 (Figure 2B; P > 0.05, ANOVA), and total
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FIGURE 2 | Nilotinib affects striatal phosphorylation of Cdk5 and
DARPP-32 in naïve mice.Western blot analysis was performed on striatal
extracts from naïve mice that received intraperitoneal injections of nilotinib at
doses of 5, 10, 25, or 50 mg/kg 30 min before they were sacriﬁced. (A) Optical
density measurements of striatal Cdk5-pTyr15 and total Cdk5. Values are
means ± SEM (n = 5). *P < 0.05 versus mice treated with vehicle; one-way
ANOVA [F (4,20) = 22.957] followed by Scheffe test. (B) Optical density
measurements of striatal DARPP-32-pThr75, DARPP-32-pThr34, and total
DARPP-32. Values are means ± SEM (n = 5). *P < 0.05 versus mice treated
with vehicle; one-way ANOVA [F (4,20) = 93.125] followed by Scheffe test.
DARPP-32 (Figure 2B; P > 0.05, ANOVA) were found. Thus,
systemic administration of nilotinib could inhibit striatal phos-
phorylation of both Cdk5 at Tyr15, the substrate site targeted by
c-Abl (Zukerberg et al., 2000; Dhavan and Tsai, 2001; Zhang et al.,
2007), and DARPP-32 at Thr75, the substrate site targeted by Cdk5
(Greengard, 2001), in naïve mice.
To test if D1R- and D2R-mediated signals differentially
affected the decrease of phosphorylation of Tyr15-Cdk5 and
Thr75-DARPP-32 by nilotinib, we next performed western blot-
ting on the striatal extracts from naïve mice injected with
nilotinib (25 mg/kg) in combination with the D1-agonist A-
68930 (2 mg/kg), D1-antagonist SCH-23390 (0.5 mg/kg), D2-
agonist quinpirole (3 mg/kg), or D2-antagonist raclopride
(1 mg/kg), 30 min before they were sacriﬁced. Nilotinib-
induced decrease of striatal levels of Cdk5-pTyr15 (Figure 3A;
P > 0.05, ANOVA) and DARPP-32-pThr75 (Figure 3B;
P > 0.05, ANOVA) was unchanged by A-68930 or SCH-
23390. In contrast, it was signiﬁcantly enhanced by quinpi-
role (Figures 3C,D; P < 0.05, ANOVA), but antagonized by
raclopride (Figures 3C,D; P < 0.05, ANOVA). In addition,
striatal expression of total Cdk5, total DARPP-32, and DARPP-
32-pThr34 was not affected by any dopaminergic compounds
(Figures 3A–D). These ﬁndings indicate that D2R, but not D1R,
activation could positively affect the nilotinib-induced decrease
of striatal phosphorylation of Tyr15-Cdk5 and Thr75-DARPP-
32.
NILOTINIB SYNERGIZES WITH A D1-AGONIST FOR STRIATAL c-Fos
INDUCTION IN NAÏVE MICE
A striking feature of the neuronal responses to dopamine recep-
tor stimulation in the striatum is a rapid induction of c-Fos,
one of the products of the immediate-early genes (LaHoste
et al., 1993; Canales and Graybiel, 2000). Strong interactive and
synergistic effects of D1Rs and D2Rs have been reported to
affect these neuronal responses (LaHoste et al., 1993; Canales
and Graybiel, 2000). To assess whether nilotinib could induce
striatal c-Fos expression, we performed c-Fos immunostaining
on striatal sections from mice that received A-68930 (2 mg/kg)
alone, quinpirole (3 mg/kg) alone, nilotinib (25 mg/kg) alone,
A-68930 (2 mg/kg) + quinpirole (3 mg/kg), or A-68930
(2 mg/kg) + nilotinib (25 mg/kg) at 120 min before they
were sacriﬁced. Microscopic images showed only a few c-Fos-
positive nuclei in the striatum of mice that received A-68930
alone (Figures 4A,F), quinpirole alone (Figures 4B,G), or nilo-
tinib alone (Figures 4C,H). In contrast, a robust induction
of c-Fos in striatal neurons was found in mice injected with
the combination of A-68930 and quinpirole (Figures 4D,I) and
in those injected with the combination of A-68930 and nilo-
tinib (Figures 4E,J). These visual impressions were conﬁrmed
by densitometric analyses (Figure 4K). In accordance with
the fact that dopamine D1/D2 synergism is required for stri-
atal Fos induction in the intact striatum (LaHoste et al., 1993),
a signiﬁcant increase in the number of c-Fos-labeled nuclei
was found in mice injected with the combination of A-68930
and quinpirole (Figure 4K; P < 0.001, unpaired two-tailed
t-test), compared to mice injected with A-68930 alone. Inter-
estingly, we also found a signiﬁcant increase in the number
of c-Fos-labeled nuclei in mice injected with the combination
of A-68930 and nilotinib (Figure 4K; P < 0.001, unpaired
two-tailed t-test), compared to mice injected with A-68930
alone. These ﬁndings suggest that, like a D2-agonist, nilo-
tinib can synergize with a D1-agonist for inducing striatal c-Fos
expression.
NILOTINIB ATTENUATES MOTOR IMPAIRMENTS IN MPTP MICE
To gain insight into the antiparkinsonian actions of nilotinib, we
conducted an experiment in the MPTP mouse model. The exper-
imental design is shown in Figure 5A (see also Materials and
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FIGURE 3 | Dopaminergic modulation of nilotinib effects on striatal
phosphorylation ofTyr15-Cdk5 andThr75-DARPP-32 in naïve mice.
Vehicle or nilotinib (NTB; 25 mg/kg) treated mice were administered saline,
A-68930 (2 mg/kg), SCH-23390 (0.5 mg/kg), quinpirole (3 mg/kg), or raclopride
(1 mg/kg) 30 min before sacriﬁce. Striatal tissue extracts were prepared and
subjected to western blotting. (A)Western blot analysis of striatal levels of
Cdk5-pTyr15 and total Cdk5 in mice treated with saline + vehicle,
NTB + saline, NTB + A-68930, or NTB + SCH-23390. Values are
means ± SEM (n = 5). (B)Western blot analysis of striatal levels of
DARPP-32-pThr75, DARPP-32-pThr34, and total DARPP-32 in mice treated
with saline + vehicle, NTB + saline, NTB + A-68930, or NTB + SCH-23390.
Values are means ± SEM (n = 5). (C)Western blot analysis of striatal levels of
Cdk5-pTyr15 and total Cdk5 in mice treated with saline + vehicle,
NTB + saline, NTB + quinpirole, or NTB + raclopride. Values are
means ± SEM (n = 5). *P < 0.05 versus mice treated with NTB + saline;
one-way ANOVA [F (3,16) = 44.790] followed by Scheffe test. (D)Western blot
analysis of striatal levels of DARPP-32-pThr75, DARPP-32-pThr34, and total
DARPP-32 in mice treated with saline + vehicle, NTB + saline,
NTB + quinpirole, or NTB + raclopride. #P < 0.05 versus mice treated with
NTB + saline; one-way ANOVA [F (3,16) = 116.883] followed by Scheffe test.
Methods). There was a marked (>80%) loss of TH, the rate-
limiting enzyme in dopamine synthesis, in MPTP-treated mice
compared to saline-treated mice (Figure 5B; P < 0.01, ANOVA).
Consistent with a recent landmark report (Viaro et al., 2010),
MPTP-treated mice exhibited overt behavioral abnormalities as
a parkinsonian-like phenotype (Figures 5C–J). Compared to con-
trol mice, MPTP-treated mice showed signiﬁcant motor deﬁcits,
as determined by beam walking (Figure 5C; P < 0.05, ANOVA),
bar (Figure 5D; P < 0.05, ANOVA), horizontal wire (Figure 5E;
P < 0.05, ANOVA), and rotarod tests (Figure 5F; P < 0.05,
ANOVA). A foot printing test showed a signiﬁcant decrease
in stride length of both the hindpaw (Figure 5G; P < 0.001,
ANOVA) and forepaw (Figure 5H; P < 0.001, ANOVA) and a
signiﬁcant increase in the overlap length (Figure 5I; P < 0.01,
ANOVA) in MPTP-treated mice, compared to saline-treated
mice.
Notably, all the behavioral tests (Figures 5C–J) revealed sig-
niﬁcant recovery of impaired motor performances after intraperi-
toneal injection of nilotinib in MPTP mice, compared to vehicle-
treated MPTP mice. The beam walking (Figure 5C) and bar
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FIGURE 4 | Synergism of nilotinib and a D1-agonist for striatal c-Fos
induction in naïve mice. c-Fos immunostaining was performed on striatal
sections from mice that received A-68930 (2 mg/kg) alone, quinpirole
(3 mg/kg) alone, nilotinib (25 mg/kg) alone, A-68930 (2 mg/kg) + quinpirole
(3 mg/kg), or A-68930 (2 mg/kg) + nilotinib (25 mg/kg) 120 min before they
were sacriﬁced. n = 5 per group. (A–J) Photomicrographs of striatal sections
stained for c-Fos from mice treated with A-68930 (A,F), quinpirole (B,G),
nilotinib (C,H), A-68930 + quinpirole (D,I), and A-68930 + nilotinib (E,J). Scale
bar: 1 mm (A–E), 100 mm (F–J). (K) Density measurements of c-Fos-labeled
nuclei in the dorsal striatum. Values are means ± SEM (n = 25). ***P < 0.001
versus mice treated with A-68930 alone, those with quinpirole alone, or those
with nilotinib alone; unpaired two-tailed t -test.
(Figure 5D) tests showed a signiﬁcant decrease in traveling time
and in catalepsy-like immobilization after administration of nilo-
tinib at a dose of 25 mg/kg (P < 0.05, ANOVA), but not at a
dose of 10 mg/kg (P > 0.05, ANOVA). The horizontal wire test
(Figure 5E) showed a signiﬁcant increase in pass rate following
injection of nilotinib at doses of 10 mg/kg (P < 0.05, ANOVA)
and 25 mg/kg (P < 0.05, ANOVA). The rotarod test (Figure 5F)
showed a signiﬁcant increase in latency to fall after administration
of nilotinib at a dose of 25 mg/kg (P < 0.05, ANOVA), but not at
a dose of 10 mg/kg (P > 0.05, ANOVA). On the foot printing test,
a signiﬁcant increase in stride length of the hindpaw was found
after nilotinib administration at a dose of 25 mg/kg (Figure 5G;
P < 0.05, ANOVA), but not at a dose of 10 mg/kg (P > 0.05,
ANOVA), while that of the forepaw was found after administra-
tion of nilotinib at doses of 10 and 25 mg/kg (Figure 5H; P < 0.05,
ANOVA). The foot printing test also showed a signiﬁcant decrease
in overlap length after administration of nilotinib at doses of
10 mg/kg (Figure 5I; P < 0.01,ANOVA) and 25 mg/kg (P < 0.001,
ANOVA). These observations indicate that systemic administra-
tion of nilotinib could attenuate the motor impairments caused
by striatal dopamine depletion in MPTP mice.
NILOTINIB REVERSES ABNORMALLY INCREASED STRIATAL
PHOSPHORYLATION OF Tyr15-Cdk5 and Thr75-DARPP-32 in MPTP MICE
To test if nilotinib actually inhibited striatal phosphorylation of
Cdk5 and DARPP-32 in MPTP mice, we performed western
blot analysis on striatal extracts from MPTP mice that received
nilotinib (25 mg/kg) 30 min before they were sacriﬁced. A sig-
niﬁcant increase in the striatal levels of Cdk5-pTyr15 (Figure 6A;
P < 0.01, ANOVA), but not of total Cdk5 (Figure 6A; P > 0.05,
ANOVA), was found in MPTP mice, compared to control mice.
Nilotinib treatment reversed the abnormally elevated striatal lev-
els of Cdk5-pTyr15 (Figure 6A; P < 0.01, ANOVA) to the control
baseline in MPTP mice. We also found a signiﬁcant increase
in striatal levels of DARPP-32-pThr75 (Figure 6B; P < 0.01,
ANOVA), but not of DARPP-32-pThr34 (Figure 6B; P > 0.05,
ANOVA) and total DARPP-32 (Figure 6B; P > 0.05, ANOVA),
in MPTP mice compared to control mice. Nilotinib treatment
reversed the abnormally elevated striatal levels of DARPP-32-
pThr75 to the control baseline inMPTPmice (Figure 6B; P < 0.01,
ANOVA). Thus, nilotinib could normalize the increased activ-
ity of Cdk5/DARPP-32-Thr75 signaling in the striatum of MPTP
mice.
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FIGURE 5 | Effects of nilotinib on MPTP-induced motor deficits in mice.
(A) Experimental design. Mice were trained for behavioral tests for three
consecutive days before MPTP administration. Mice received intraperitoneal
administration of MPTP (20 mg/kg × 4) or equivalent volume of saline 3 days
before the behavioral study. All the behavioral tests and western blots were
carried out 30 min after intraperitoneal injection of vehicle or nilotinib (NTB) at
a dose of 10 or 25 mg/kg. Vehicle-treated mice received an equivalent volume
of 0.5% aqueous carboxymethyl cellulose. (B)Western blot analysis of striatal
levels of tyrosine hydroxylase (TH) in mice treated with saline + vehicle,
saline + NTB, MPTP + vehicle, or MPTP + NTB. Values are means ± SEM
(n = 5). **P < 0.01 versus mice with saline-vehicle; one-way ANOVA
[F (3,16) = 30.73] followed by Scheffe test. (C–J) Behavioral studies. All the
values are expressed as means ± SEM. (C) Beam walking test (n = 11–14 per
group). *P < 0.05 versus saline-treated mice injected with vehicle or nilotinib
(25 mg/kg); #P < 0.05 versus MPTP-treated mice injected with vehicle;
one-way ANOVA [F (4,61) = 4.31] followed by Newman–Keuls test. (D) Bar
test (n = 9–10 per group). *P < 0.05 versus saline-treated mice injected with
vehicle or nilotinib (25 mg/kg); #P < 0.05 versus MPTP-treated mice injected
with vehicle; one-way ANOVA [F (4,43) = 5.97] followed by Newman–Keuls
test. (E) Horizontal wire test (n = 3 per group: the number of individuals per
each group was 14–19). *P < 0.05 versus saline-treated mice injected with
vehicle or nilotinib (25 mg/kg); #P < 0.05 versus MPTP-treated mice injected
with vehicle; one-way ANOVA [F (4,10) = 7.63] followed by Newman–Keuls
test. (F) Rotarod test (n = 14–28 per group). *P < 0.05 versus saline-treated
mice injected with vehicle or nilotinib (25 mg/kg); #P < 0.05 versus
MPTP-treated mice injected with vehicle; one-way ANOVA [F (4,93) = 5.19]
followed by Newman–Keuls test. (G) Foot printing test of stride length of
hindpaw (n = 6–14 per group). ***P < 0.001 versus saline-treated mice
injected with vehicle or nilotinib (25 mg/kg); #P < 0.05 versus MPTP-treated
mice injected with vehicle; one-way ANOVA [F (4,43) = 17.24] followed by
Fisher’s PLSD test. (H) Foot printing test of stride length of forepaw
(n = 6–13 per group). ***P < 0.001 versus saline-treated mice injected with
vehicle or nilotinib (25 mg/kg); #P < 0.05 versus MPTP-treated mice injected
with vehicle; one-way ANOVA [F (4,42) = 17.38] followed by Fisher’s PLSD
test. (I) Foot printing test of overlap (n = 6–13 per group). **P < 0.01 versus
saline-treated mice injected with vehicle or nilotinib (25 mg/kg); ##P < 0.01,
###P < 0.001 versus MPTP-treated mice injected with vehicle; one-way
ANOVA [F (4,42) = 5.52] followed by Fisher’s PLSD test. (J) Representative
images of the foot prints of saline-treated control mice, MPTP-treated mice
injected with vehicle, and MPTP-treated mice injected with NTB (25 mg/kg).
DISCUSSION
Our results demonstrated the following four major ﬁndings: (i)
nilotinib inhibited striatal phosphorylation of both Tyr15-Cdk5
and Thr75-DARPP-32 in naïve and MPTP mice, (ii) nilotinib-
induced inhibition of striatal phosphorylation of Tyr15-Cdk5
and Thr75-DARPP-32 was positively affected by D2R-mediated
signaling activity in naïve mice, (iii) like a D2-agonist, nilo-
tinib synergized with a D1-agonist for inducing striatal c-Fos
expression in naïve mice, and (iv) nilotinib attenuated motor
impairments caused by striatal dopamine deﬁciency in MPTP
mice. On the basis of these ﬁndings, we suggest that nilo-
tinib might exert antiparkinsonian effects by inhibiting activity
of the c-Abl/Cdk5/DARPP-32 signaling pathway in the stria-
tum. DARPP-32 integrates the activities of dopaminergic and
glutamatergic transmission in the striatum (Svenningsson et al.,
2004; Fernandez et al., 2006), and is, therefore, thought to be
a key regulator for the emergence of PD symptoms (Green-
gard, 2001). It has been suggested that a major mechanism
by which dopamine and glutamate produce opposing physio-
logical effects involves a positive feedback loop that ampliﬁes
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FIGURE 6 | Nilotinib affects striatal phosphorylation of Cdk5 and
DARPP-32 in MPTP mice. Saline- or MPTP-treated mice were
administered vehicle or nilotinib (NTB; 25 mg/kg) 30 min before they were
sacriﬁced. Striatal tissue extracts were prepared and subjected to western
blotting. (A) Western blot analysis of striatal levels of Cdk5 and
Cdk5-pTyr15 in mice treated with saline + vehicle (control),
MPTP + vehicle, or MPTP + NTB. Values are means ± SEM (n = 5).
**P < 0.01 versus mice with saline + vehicle or MPTP + NTB; one-way
ANOVA [F (2,12) = 11.91] followed by Scheffe test. (B) Western blot
analysis of striatal levels of DARPP-32-pThr75, DARPP-32-pThr34, and total
DARPP-32 in mice treated with saline + vehicle (control), MPTP + vehicle,
or MPTP + NTB. Values are means ± SEM (n = 5). **P < 0.01 versus
mice with saline + vehicle or MPTP + NTB; one-way ANOVA
[F (2,12) = 11.77] followed by Scheffe test.
their mutually antagonistic actions (Greengard, 2001). In such
a scenario, glutamate inputs would increase phosphorylation of
DARPP-32 at Thr75, the substrate site targeted by Cdk5, and
thereby antagonize postsynaptic dopamine functions. Given the
evidence that c-Abl can activateCdk5 by phosphorylating its Tyr15
residue (Zukerberg et al., 2000; Dhavan and Tsai, 2001; Zhang
et al., 2007), we hypothesized that nilotinib, a c-Abl inhibitor,
might exert antiparkinsonian actions by inhibiting striatal phos-
phorylation of Tyr15-Cdk5, resulting in decreased activity of
glutamate/Cdk5/DARPP-32-pThr75 signaling in the striatum.
This hypothesis is supported by the fact that Cdk5-pTyr15 is a
striatal-enriched phosphoprotein that is highly concentrated in
the striatal matrix compartment (Morigaki et al., 2011; Yama-
mura et al., 2013), which has a tight link with the striatal motor
functions (Crittenden and Graybiel, 2011). As in our previous
study (Yamamura et al., 2013), the present study also suggests
a new idea that c-Abl might be an important regulator of stri-
atal D2R-mediated signals. However, the precise mechanism by
which c-Abl activity is modulated by the interactions between
dopamine and glutamate transmission in the striatum remains
to be elucidated.
Current pharmacotherapy for parkinsonian motor symptoms
largely depends on the activation of dopamine receptors. L-DOPA
therapy still remains the gold standard for treating PD; however,
after long-term exposure to L-DOPA, PD patients become refrac-
tory to treatment (Jankovic, 2005), probably a result, in part, of
the down-regulation of D2Rs (Thobois et al., 2004). Moreover,
patients often manifest L-DOPA-induced dyskinesias (Jankovic,
2005), a result, in part, of maladaptive synaptic plasticity at
D1Rs coupled with glutamate receptors (Jenner, 2008; Murer and
Moratalla, 2011). Exploration of alternative and additional ther-
apeutic tools, particularly drugs that can exert anti-PD effects
without direct activation of dopamine receptors, is therefore pru-
dent. In this study, we provide a novel ﬁnding that in MPTP mice,
striatal motor behaviors were normalized by systemic adminis-
tration of nilotinib, a drug that is now clinically used to treat
chronic myeloid leukemia (Weisberg et al., 2006; Blay and von
Mehren, 2011). Together with the reported experimental ﬁnd-
ings that nilotinib (Hebron et al., 2013) and other c-Abl inhibitors
(Ko et al., 2010; Imam et al., 2011, 2013) also play a protective
role against the neurodegeneration of dopamine-producing cells
in the substantia nigra of mice, our results suggest that nilotinib
may serve as an alternative agent for attenuating motor symptoms
and disease progression of PD.
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